In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Lilly’s Verzenio was approved to treat early breast cancer in March 2023 and metastatic breast cancer in September 2017. It has a wholesale acquisition cost of $4,082.52 for 14 tablets. Novartis’ ...

Verzenio is an oral tablet taken twice daily and available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg. Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and ...

A combination regimen of avutometinib (VS-6766), abemaciclib (Verzenio), and fulvestrant (Faslodex) demonstrated early clinical activity and manageable safety in patients with hormone receptor ...

In a significant move to streamline and promote pharmaceutical exports, the Directorate General of Foreign Trade (DGFT) has issued Public Notice announcing the fixation of a new Standard Input Output ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.

Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.

This is compared to NVO's next-gen daily oral candidate, amycretin at 100 mg with -13.1% in weight loss by Week 12 and VKTX's daily oral candidate, VK2735 at 100 mg with -14.7% in weight loss by ...

For abemaciclib, you have 3 kinds of tablet strengths: 50 mg, 100 mg, and 150 mg. 9 We don’t use the 200-mg tablet. We have 200-mg tablets for ribociclib. We start at 150 mg twice daily for ...

As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations As combination therapy ...